TrialJournal of neurology2025

Challenges in multinational rare disease clinical studies during COVID-19: regulatory assessment of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease.

Benedikt Schoser et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.